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Abstract
Background: The importance of arachidonic acid (ARA) among the elderly has recently gained increased attention.
The effects of ARA supplementation in the elderly are not fully understood, although ARA is considered to be
associated with various diseases. We investigate whether ARA supplementation to Japanese elderly subjects affects
clinical parameters involved in cardiovascular, inflammatory, and allergic diseases. We also examine the levels of
ARA metabolites such as prostanoids during intervention.
Methods: We conducted a randomized, double-blind and placebo-controlled parallel group intervention trial. ARA-
enriched oil (240 or 720 mg ARA per day) or placebo was administered to Japanese healthy men and women
aged 55-70 years for 4 weeks followed by a 4-week washout period. The fatty acid contents of plasma
phospholipids, clinical parameters, and ARA metabolites were determined at baseline, 2, 4, and 8 weeks.
Results: The ARA content in plasma phospholipids in the ARA-administrated groups increased dose-dependently
and was almost the same at 2 weeks and at 4 weeks. The elevated ARA content decreased to nearly baseline
during a 4-week washout period. During the supplementation and washout periods, no changes were observed in
eicosapentaenoic acid and docosahexaenoic acid contents. There were no changes in clinical blood parameters
related to cardiovascular, inflammatory and allergic diseases. ARA supplementation did not alter the level of ARA
metabolites such as urinary 11-dehydro thromboxane B2, 2,3-dinor-6-keto prostaglandin (PG) F1a and 9,15-dioxo-
11a-hydroxy-13,14-dihydro-2,3,4,5-tetranor-prostan-1,20-dioic acid (tetranor-PGEM), and plasma PGE2 and lipoxin A4.
ARA in plasma phospholipids was not correlated with ARA metabolite levels in the blood or urine.
Conclusion: These results indicate that ARA supplementation, even at a relatively high dose, does not increase
ARA metabolites, and suggest that it does not induce cardiovascular, inflammatory or allergic diseases in Japanese
elderly individuals.
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Arachidonic acid (ARA) is an n-6 essential fatty acid
that is a major constituent of biomembranes. It is con-
verted into lipid mediators that exert various physiologi-
cal actions. ARA is synthesized in the body from dietary
linoleic acid (LA) and additionally most adults consume
50-250 mg/day of ARA from foodstuffs [1-3].
The consumption of ARA in breast milk is very impor-
tant for infant development since the activity from LA
conversion to ARA is low in infant [4]. The conversion of
LA to ARA declines with age [5], and the importance of
ARA supplementation among the elderly has recently
gained increased attention. It has been reported that sup-
plementation with ARA among the elderly improves cog-
nitive response [6] and coronary flow velocity reserve [7]
and some animal studies support these findings [8-11].
However, many studies show that lipid mediators
derived from ARA are associated with various diseases.
For example, thromboxane A2 (TXA2) is associated with
cardiovascular diseases via its activation of thrombogeni-
city and vasoconstriction, whereas prostaglandin E2
(PGE2) leads to inflammation and might enhance tumor
growth [12-14]. Levels of the urinary TXA2 metabolite,
11-dehydro TXB2, have been shown to be higher in
patients with heart failure (3.4-fold), ischemic heart dis-
ease (1.4-fold) [15] and essential hypertension [16].
Plasma PGE2 levels are also high in patients with ulcera-
tive colitis [17] and advanced periodontitis [18], and
levels of its urinary metabolite, tetranor-PGEM, are epi-
demiologically higher in colorectal cancer [19]. The rela-
tionship between lipids mediators and diseases is
speculated based on the fact that cyclooxygenase (COX)
inhibitors are effective against these conditions [14,20].
Many clinical trials of ARA supplementation have been
done on infants [4], but there are a few reports describe
the administration of ARA or ARA-containing oil to
adults [21-23]. Among healthy males who consumed 1.5
g/day of ARA (as free ARA) for 50 days [21,22] or 838
mg/day of ARA for 4 weeks [23] in randomized controlled
studies, platelet aggregation did not change and adverse
effects did not occur. Both urinary 11-dehydro TXB2 and
2,3-dinor-6-keto PGF1a slightly increased in the former
study [22]. However, it remains unclear whether ARA
intake evokes the clinical parameters in the speculated dis-
eases in the elderly. It is also unclear whether ARA intake
increases lipid mediators derived from ARA in the elderly.
The present study investigates the effects of 240 or
720 mg/day of ARA, which is much more than that
derived from food, on Japanese healthy elderly indivi-
duals. We determined clinical parameters of cardiovas-
cular, inflammatory, and allergic diseases in blood as
well as ARA content in plasma phospholipids and urin-
ary and plasma lipid mediators. Correlations between
ARA content in plasma phospholipids and lipid media-
tor concentrations were also determined.
Materials and methods
Study design
This randomized, double-blind and placebo-controlled
parallel group intervention trial evaluated the effects of
daily ARA supplementation on cardiovascular disease
and/or inflammation. The Ethics Committee on Human
Experimentation of Suntory Holdings Ltd. approved the
study, which conformed to the principles set forth in
the Declaration of Helsinki. Written informed consent
was obtained from the participants of this study. Physio-
logical parameters and blood and urine were sampled at
the time of recruitment starting in August 2010. One
hundred and eighteen participants were screened and
randomly assigned to placebo, low-ARA or high-ARA
groups. Participants received 10 gelatin-capsules con-
taining either ARA or a placebo every morning for 4
w e e k sf o l l o w e db ya4 - w e e kw a s h o u tp e r i o d .B l o o da n d
u r i n ew e r es a m p l e d ,as t u d yd i a r yw a sd i s t r i b u t e da n d
collected and dietary intake was assessed at baseline
(week 0, within 4 weeks of recruitment) and again at 2,
4 and 8 weeks later. The fatty acid composition of the
oils used in this study is shown in Table 1. The placebo
Table 1 Fatty acid composition of test capsules
Fatty acids
1 Group
(%) Placebo Low-ARA High-ARA
14:0 0.0 0.2 0.5
15:0 0.0 0.0 0.2
16:0 12.2 11.9 11.3
16:1 1.2 0.8 0.0
17:0 0.0 0.1 0.3
18:0 2.8 4.5 8.1
18:1 72.3 50.3 6.3
18:2n-6 9.6 9.4 8.9
18:3n-6 0.0 0.9 2.6
18:3n-3 0.7 0.6 0.4
20:0 0.4 0.6 0.9
20:1 0.3 0.3 0.4
20:2n-6 0.0 0.2 0.7
20:3n-6 0.0 1.4 4.0
20:4n-6 0.0 14.2 42.9
22:0 0.1 1.2 3.3
22:4n-6 0.0 0.2 0.5
24:0 0.0 2.6 7.5
Others 0.4 0.6 1.2
114:0, myristic acid; 15:0, pentadecanoic acid; 16:0; palmitic acid; 16:1,
palmitoleic acid; 17:0, heptadecanoic acid; 18:0, stearic acid; 18:1, oleic acid;
18:2n-6, linoleic acid; 18:3n-6, g-linolenic acid; 18:3n-3, a-linolenic acid; 20:0,
eicosanoic acid; 20:1, eicosenic acid; 20:2n-6, eicosadienoic acid; 20:3n-6,
dihomo-g-linolenic acid; 20:4n-6, arachidonic acid; 22:0, behenic acid; 22:4n-6,
docosatetraenoic acid; and 24:0, lignoceric acid.
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olive oil. The high-ARA group consumed 1700 mg/day
of an ARA-enriched edible oil derived from Mortierella
alpina (SUNTGA40S; 720 mg/day of ARA) [24]. The
low-ARA group received 570 mg/day of ARA-enriched
o i la n d1 1 3 0m g / d a yo fo l i v eo i l( 2 4 0m g / d a yo fA R A ) .
Blood and urine samples were obtained after an over-
night fast for > 10 hours on the morning of each assess-
ment. Cardiovascular risk parameters included
prothrombin time (PT), activated partial thromboplastin
time (APTT), antithrombin III (ATIII), high-sensitivity
C-reactive protein (hs-CRP) and adiponectin. Allergic
parameters included nonspecific immunoglobulin E
(IgE) levels and eosinophils (EO). Inflammatory para-
meters comprised C-reactive protein (CRP), interleukin-
6 (IL-6) and tumor necrosis factor-a (TNF-a) levels.
Urinalysis was conducted for quantitative analysis of
creatinine (Cre) and qualitative analyses of protein, glu-
cose and urobilinogen.
Participants
Healthy men and women aged 55-70 years living in
Tokyo and its environs were recruited. Exclusion criteria
were as follows: allergy to gelatin or olive oil; continuous
consumption of drugs or supplements that affect lipid
metabolism; continuous intake of non-steroidal anti-
inflammatory or anti-allergic drugs; a history of serious
disorders such as cardiac infarction, cerebral infarction,
stroke, cancer, asthma; and clinically significant systemic
diseases. Participants were randomly assigned to the
three groups matched by gender, age, hs-CRP, PT and
estimated ARA content (%) in plasma phospholipids. To
quickly estimate the ARA content in plasma phospholi-
pids at the recruitment, the estimated ARA content was
calculated from triglycerides (TG, mg/dL), phospholipids
(PL, mg/dL) and the ARA content in total plasma fatty
acids as: (ARA content in total plasma fatty acids)×(TG
+ PL)/PL. This rough estimation is based on the fact
that the ARA content is much smaller in plasma TG
than in plasma PL (the ARA in plasma TG is negligibly-
small for the rough estimation), and used only for quick
assignment to the three groups.
Chemicals and apparatus
We purchased 11-dehydro TXB2, 9,15-dioxo-11a-
hydroxy-13,14-dihydro-2,3,4,5-tetranor-prostan-1,20-
dioic acid (tetranor-PGEM), lipoxin A4 (LXA4), 11-dehy-
dro TXB2-d4, 9,15-dioxo-11a-hydroxy-2,3,4,5-tetranor-
prostan-1,20-dioic-13,13,14,14,15,15-d6 acid (tetranor-
PGEM-d6), and LXA4-d5 from Cayman Chemical (Ann
Arbor, MI, USA). Fatty acid methyl esters were chroma-
tographically separated and detected using an Agilent
6890 GLC system (Agilent Technologies, Santa Clara,
CA, USA) equipped with a Supelco SP-2330 column (30
m×0 . 3 2m m×0 . 2μm, Sigma-Aldrich, St. Louis, MO,
USA). Lipid mediators were chromatographically sepa-
rated and detected using an Agilent 1200 HPLC system
(Agilent Technologies) equipped with a Cadenza CD-
C18 column (3 μm, 2 mm i.d. × 150 mm, Imtakt,
Kyoto, Japan) and a 4000 Q TRAP with electrospray
interface (AB SCIEX, Foster City, CA, USA).
Fatty acid analysis
Lipids in plasma were extracted and purified by the
method of Folch et al. [25]. Fatty acid residues in lipid
fractions were analyzed by the method of Sakuradani et
a l .[ 2 6 ] .I nb r i e f ,e a c hf r a c t i o nw a si n c u b a t e dw i t ha n
internal standard (pentadecanoic acid) in methanolic
HCl at 50°C for 3 h to transmethylate fatty acid residues
to fatty acid methyl esters, which were extracted with n-
hexane and analyzed by capillary gas-liquid chromato-
graphy. Plasma was directly transmethylated without
extraction or fractionation when we calculated the esti-
mated ARA content in plasma phospholipids.
Analysis of urinary metabolites of lipid mediators
Urine samples were stored at -80°C for 5-41 days before
measurement of metabolites.
Urinary 11-dehydro TXB2 was measured by LC-MS/
M S .U r i n es a m p l e s( 0 . 5m L ) ,t ow h i c h1 1 - d e h y d r o
TXB2-d4 was added as an internal standard, were
diluted with 1 mmol/L HCl to a final volume of
approximately 3 mL and left for 1 h at room tempera-
ture. The mixtures were applied to preconditioned SPE
cartridges (Empore disk cartridge C18-SD, 3M, St. Paul,
MN, USA), and the cartridges were washed with 1
mmol/L HCl, water and hexane. 11-Dehydro TXB2 and
11-dehydro TXB2-d4 were then eluted with 1 mL of
hexane/ethyl acetate (1/1, v/v). The eluates were dried
by centrifugal evaporation, re-dissolved in 0.1 mL of
acetonitrile/water/formic acid (250/750/1, v/v/v) and
then transferred to brown glass vials at 10°C. Portions
of these elute (20 μL) were injected into LC-MS/MS.
Solvent A was 5 mM ammonium acetate (pH 5.5) and
solvent B was acetonitrile.T h es e p a r a t i o nw a sp e r -
formed in an isocratic mode with 35% solvent B at a
flow rate of 0.2 mL/min and a column temperature of
40°C. The mass spectrometer was operated in the nega-
tive ion mode. 11-Dehydro TXB2 and 11-dehydro
TXB2-d4 were detected in selected reaction monitoring
(SRM) mode by monitoring mass transitions of m/z 367
® 305 for 11-dehydro TXB2,a n dm/z 371 ® 309 for
11-dehydro TXB2-d4 at a collision energy of -23 V.
Urinary tetranor-PGEM was measured by LC-MS/MS
according to the modified method of Murphey et al.
[27]. Urine samples (0.1 mL) to which tetranor-PGEM-
d6 was added as an internal standard were diluted with
1 mmol/L HCl to a final volume of approximately 1 mL.
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methylhydroxylamine hydrochloride in 1.5 M sodium
acetate buffer pH 5 (16%, w/v) and left for 1 h at
room temperature. The mixtures were applied to SPE
cartridges as described above, and the cartridges were
washed with 1 mmol/L HCl. Tetranor-PGEM and tet-
ranor-PGEM-d6 were then eluted with 1 mL of ethyl
acetate. The eluates were dried, re-solved and trans-
ferred as described above. Portions of these elute (20
μL) were injected into LC-MS/MS. Solvent A was
water/formic acid (100/0.2, v/v) and solvent B was
acetonitrile/methanol/formic acid (95/5/0.2, v/v/v). The
separation was performed at a flow rate of 0.2 mL/min
and a column temperature of 60°C using the following
linear gradient: 0-4.8 min, 30 to 94% solvent B; 4.8-
5.75 min, 94 to 30% solvent B; 5.75-14.8 min, 30% sol-
vent B. The mass spectrometer was operated in the
negative ion mode. Tetranor-PGEM and tetranor-
PGEM-d6 were detected in SRM mode by monitoring
mass transitions at m/z 385 ® 336 for tetranor-PGEM,
and m/z 391 ® 342 for tetranor-PGEM-d6 at a colli-
sion energy of -25 V.
Urinary 2,3-dinor-6-keto PGF1a was measured using
an enzyme-linked immunosorbent assay (EIA) kit (2,3-
dinor-6-keto Prostaglandin F1a EIA Kit, Cayman Chemi-
cal Company). Urine samples (0.5 mL) were diluted
with 1 M sodium citrate buffer pH 4 to a final volume
of approximately 1 mL and then vigorously mixed with
4 mL of ethyl acetate. The mixtures were separated by
centrifugation and the upper phases were collected. The
liquid-liquid extraction with ethyl acetate was performed
three times and three upper phases of one urine sample
were pooled. The pooled extracts were dried by centri-
fugal evaporation and re-dissolved in assay buffer for
analysis.
Analysis of plasma lipid mediators
Blood samples for lipid mediators were collected in
vacuum blood collection tubes containing EDTA-2Na
and a final concentration of approximately 18 μMo f
sodium indomethacin. Plasma separated within 1 h was
then stored at -80°C for 10-93 days before measurement
of mediators.
Plasma PGE2 was measured using an EIA kit (Prosta-
glandin E2 EIA Kit - Monoclonal, Cayman Chemical
Company). Plasma samples (1 mL) to which 5 μL of for-
mic acid was added were diluted with 1 mmol/L HCl to
a final volume of approximately 3 mL. The mixtures
were applied to preconditioned SPE cartridges (BondE-
lut C18, Agilent Technologies), and the cartridges were
washed with 1 mmol/L HCl and hexane. PGE2 was then
eluted with 1 mL of ethyl acetate/methanol (99/1, v/v).
The eluates were dried by centrifugal evaporation and
re-dissolved in assay buffer for analysis.
Plasma LXA4 was measured by LC-MS/MS. Plasma
samples (1 mL) to which LXA4-d5 was added as an
internal standard were diluted with water/acetic acid
(1000/5, v/v) to a final volume of approximately 3 mL
and applied to preconditioned SPE cartridges (FOCUS,
20 mg/3 mL, Agilent Technologies). The cartridges were
washed with water/acetic acid (1000/5, v/v) and water.
LXA4 and LXA4-d5 were then eluted with 1 mL of
methanol/acetonitrile/acetic acid (600/300/1, v/v/v). The
eluates were dried, re-solved and transferred as
described above. Portions of these elute (20 μL) were
injected into LC-MS/MS. Solvent A was water/formic
acid (100/0.2, v/v) and solvent B was acetonitrile/metha-
nol/formic acid (95/5/0.2, v/v/v). The separation was
performed at a flow rate of 0.2 mL/min and a column
temperature of 60°C using the following linear gradient:
0-3.75 min, 50 to 98% solvent B; 3.75-5 min, 98% sol-
vent B; 5-5.75 min, 98 to 50% solvent B; 5.75-14.8 min,
50% solvent B. The mass spectrometer was operated in
the negative ion mode. LXA4 and LXA4-d5 were
detected in SRM mode by monitoring mass transitions
at m/z 351 ® 115 for LXA4,a n dm/z 356 ® 115 for
LXA4-d5 at a collision energy of -22 V.
Dietary assessment and study diary
Dietary habits during the preceding month were
assessed using the brief self-administered diet history
questionnaire (BDHQ) [28]. Dietary intake was esti-
mated using an ad hoc computer algorithm for the
BDHQ based on the Standard Tables of Food Composi-
tion in Japan [29,30]. Participants were asked to keep a
record throughout the study about intake of the test
capsules, the presence of symptoms, amount of exercise,
amount of food and alcohol consumed and the use of
medication.
Statistical analysis
Results are expressed as means ± SD. Hs-CRP values
that exceeded the upper limit of detection (1000 μg/dL)
were rounded down to 1000 μg/dL and comprised of
one measurement in the low-ARA group at baseline,
one in the placebo group, one in the low-ARA group at
2 weeks and two in the high-ARA group at 4 weeks.
For physiological parameters, blood biochemical para-
meters except hs-CRP, hematological parameters, fatty
acid composition of plasma phospholipids, urinary meta-
bolites of lipid mediators and plasma lipid mediators,
intra-group comparisons at 2, 4 or 8 weeks versus base-
line were analyzed by repeated ANOVA and Dunnett’s
test using the actual values; inter-group comparisons at
2, 4, or 8 weeks were analyzed by ANOVA and the
Tukey-Kramer test using the changes from baseline
v a l u e s .F o rh s - C R P ,i n t r a - g roup comparisons were ana-
lyzed by Friedman test and Steel test; inter-group
Kakutani et al. Lipids in Health and Disease 2011, 10:241
http://www.lipidworld.com/content/10/1/241
Page 4 of 12comparisons were analyzed by Kruskal-Wallis test and
Steel-Dwass test. For dietary intake of nutrients, intra-
group comparisons at 4 weeks versus baseline were ana-
lyzed by a paired student t-test; inter-group comparisons
at 4 weeks were analyzed by ANOVA and Tukey-Kra-
mer test. For compliance rate, inter-group comparisons
were analyzed by ANOVA and Tukey-Kramer test. For
adverse events, inter-group comparisons were analyzed
by Kruskal-Wallis test. All p values were two-tailed, and
a p value of < 0.05 was considered statistically
significant.
Results
Characteristics of the participants
One participant in the placebo group withdrew for per-
sonal reasons and another was excluded due to meeting
one of the exclusion criteria. Thus, we analyzed data
generated from 64 participants in three groups (placebo,
n=2 0 ;l o w - A R A ,n=2 2 ;a n dh i g h - A R A ,n=2 2 )
(Figure 1). The mean compliance rate was > 95% across
the three groups and did not differ significantly among
them. Side effects did not arise. The numbers of adverse
events that developed were six among five participants
in the placebo group, eight among six in the low-ARA
group and twelve among six in the high-ARA group.
None of these adverse events were severe and their fre-
quency did not significantly differ among the groups.
The adverse events were common cold (all groups),
eczema (placebo and low-ARA groups), diarrhoea (high-
ARA group), toothache (low-ARA group), and bone
fracture (placebo group).
Baseline characteristics of the three groups are shown
in Table 2. All groups were balanced with respect to
g e n d e r ,a g e ,B M I ,a l c o h o lc o nsumption, smoking status
and exercise. Neither hs-CRP, PT nor cardiovascular
risk parameters differed significantly among the groups.
The mean ARA content in plasma phospholipids ranged
from 8.2-8.8% among the three groups and other poly-
unsaturated fatty acids also did not differ among them.
Macronutrient intake during the preceding month at
baseline or at 4 weeks later did not differ among the
groups or at any time point (Table 3). The daily ARA
intake derived from food ranged from 170-200 mg/day
in all three groups with no significant differences. The
daily intakes of DHA and EPA were 300-500 mg/day
and 500-800 mg/day, respectively.
Fatty acid profiles of plasma phospholipids
The ARA content in plasma phospholipids in the high-
ARA group increased from 8.77 ± 1.32% (means ± SD)
at baseline to 14.02 ± 1.50% at 2 weeks, and was almost
t h es a m ea t4w e e k s( 1 4 . 3 3±2 . 1 4 % ) .T h ee l e v a t e d
ARA content declined almost to the initial level during
Assessed for eligibility (n=118) 
Excluded (n=52) 
 -Not meeting inclusion 
  criteria (n=45) 
 -Eligible but not  
  recruited (n=7) 
Randomized (n=66) 
High-ARA group  
(n=22) 
Low-ARA group  
(n=22) 
Placebo group  
(n=22) 
Lost to follow-up  
(n=0) 
Discontinued  
(n=0) 
Lost to follow-up  
(n=0) 
Discontinued  
(n=0) 
Lost to follow-up  
(n=0) 
Discontinued  
(n=1) 
Analyzed (n=22) 
Excluded (n=0) 
Analyzed (n=22) 
Excluded (n=0) 
Analyzed (n=20) 
Excluded (n=1) 
Figure 1 Flow diagram of participants included in the present
analysis.
Table 2 Baseline characteristics of the participants
1
Group
Characteristics
2 Placebo Low-ARA High-ARA
(n = 20) (n = 22) (n = 22)
Gender (Female) n 12 13 12
Age y 63.1 ± 3.8 62.8 ± 4.3 62.9 ± 4.2
BMI kg/m
2 21.5 ± 2.4 22.5 ± 2.0 22.5 ± 3.1
Alcohol consumption
Positive n 11 13 9
Negative n 9 9 13
Smoking status
Positive n 4 3 3
Negative n 16 19 19
Exercise
Habitual n 11 15 14
Nonhabitual n 9 7 8
hs-CRP μg/dL 113 ± 98 106 ± 153 104 ± 116
PT % 91.4 ± 8.5 91.4 ± 8.6 91.5 ± 6.5
HbA1c % 4.9 ± 0.2 4.9 ± 0.3 4.9 ± 0.4
FA composition
18:2n-6 % 18.33 ± 2.64 18.91 ± 2.16 17.78 ± 2.62
20:4n-6 % 8.27 ± 1.26 8.61 ± 0.92 8.77 ± 1.32
20:5n-3 % 2.85 ± 1.30 3.17 ± 1.42 3.59 ± 2.16
22:6n-3 % 7.83 ± 1.42 8.10 ± 1.27 8.41 ± 2.29
1Values are means ± SD. No significance among the groups (ANOVA and
Tukey-Kramer or Kruskal-Wallis tests).
2hs-CRP, high-sensitivity CRP; PT, prothrombin time; HbA1c, hemoglobin A1c;
FA, fatty acid; 18:2n-6, linoleic acid; 20:4n-6, arachidonic acid; 20:5n-3,
eicosapentaenoic acid; 22:6n-3, docosahexaenoic acid.
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The time course of the ARA increase tended to be simi-
lar in the low-ARA group. The ARA content in the low-
ARA group was 8.61 ± 0.92% at baseline, 11.30 ± 1.55%
at 2 weeks, and 11.15 ± 1.52% at 4 weeks; the value
declined during the washout period. The ARA content
in the placebo group remained unchanged throughout
the study.
In the high-ARA group, the LA content in plasma
phospholipids inversely declined from 17.78 ± 2.62% at
baseline to 14.10 ± 2.36% at 4 weeks and then increased
almost to baseline levels during the 4 week washout per-
iod (17.41 ± 2.73%) (Figure 2B). The EPA and DHA
contents in plasma phospholipids were unchanged
throughout the study period in all groups (Figure 2C
and 2D).
Clinical parameters of cardiovascular diseases and
inflammation
Changes in clinical parameters associated with cardiovas-
cular risk, allergy and inflammation are shown in Figure 3.
Although some parameters the groups or time points dif-
fered significantly, all values were within the normal
ranges and did not change according to ARA supplemen-
tation. Physiological, blood biochemical and hematological
parameters were also within normal ranges and were unaf-
fected by dose of ARA (Additional file 1, Table S1). Urin-
ary findings were normal in all groups (data not shown).
Table 3 Calculated daily nutrient intake at baseline and after four weeks of supplementation
1
Nutrient Baseline (week 0) Supplementation (week 4)
Placebo Low-ARA High-ARA Placebo Low-ARA High-ARA
Energy kcal/d 1871 ± 483 1779 ± 439 2017 ± 636 1973 ± 550 1748 ± 410 1945 ± 497
Protein g/d 73.4 ± 21.6 67.1 ± 17.2 78.0 ± 22.2 74.6 ± 21.4 68.9 ± 17.8 77.0 ± 21.4
Carbohydrate g/d 256 ± 68 234 ± 82 260 ± 91 278 ± 76 227 ± 63 259 ± 74
Total fat g/d 56.0 ± 19.1 52.8 ± 16.6 61.0 ± 21.9 56.5 ± 22.3 52.4 ± 14.8 57.5 ± 16.8
SFA g/d 16.2 ± 6.3 14.7 ± 5.0 16.3 ± 6.7 15.5 ± 8.1 14.1 ± 4.4 15.2 ± 5.2
MUFA g/d 19.3 ± 7.0 18.4 ± 6.4 21.8 ± 8.2 19.6 ± 7.6 18.4 ± 5.7 20.4 ± 6.1
PUFA g/d 13.1 ± 4.6 12.7 ± 3.6 14.8 ± 4.7 13.8 ± 4.3 12.8 ± 3.4 14.1 ± 4.0
18:2n-6 g/d 9.96 ± 3.52 9.76 ± 2.85 11.12 ± 3.60 10.59 ± 3.34 9.71 ± 2.56 10.74 ± 3.05
20:4n-6 mg/d 174 ± 56 170 ± 71 199 ± 74 172 ± 67 174 ± 73 189 ± 66
18:3n-3 g/d 1.61 ± 0.61 1.52 ± 0.48 1.79 ± 0.62 1.67 ± 0.57 1.51 ± 0.41 1.71 ± 0.51
20:5n-3 mg/d 377 ± 215 315 ± 172 447 ± 163 366 ± 197 367 ± 190 399 ± 202
22:6n-3 mg/d 616 ± 323 538 ± 267 729 ± 261 600 ± 289 611 ± 301 658 ± 306
1Values are means ± SD (n = 20, placebo group; n = 22, low-ARA; n = 22, high-ARA). No significant differences between time points (Student’s t-test) or groups
(ANOVA and Tukey-Kramer test).
2SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; 18:2n-6, linoleic acid; 20:4n-6, arachidonic acid; 18:3n-3, a-
linolenic acid; 20:5n-3, eicosapentaenoic acid; and 22:6n-3, docosahexaenoic acid.
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Page 6 of 12Levels of ARA metabolites in urine and blood
Concentrations of ARA metabolites in urine and blood
are shown in Figure 4. Initial concentrations of urinary
metabolites in the placebo, the low-ARA and the high-
ARA groups were not significantly different. After the
supplementation for 4 weeks, none of the urinary meta-
bolites in the low-ARA and high-ARA groups signifi-
cantly increased from initial levels; there were no
differences among the groups at 2 and 4 weeks. At 4
weeks, the concentrations of 11-dehydro TXB2,2 , 3 -
dinor-6-keto PGF1a and tetranor-PGEM in the low-
ARA group were 0.160 ± 0.156 (Figure 4A), 20.6 ± 16.7
(Figure 4B) and 8.41 ± 3.63 ng/mg Cre, respectively
(Figure 4C); those in high-ARA group were 0.222 ±
0.215 (Figure 4A), 16.4 ± 14.1 (Figure 4B) and 16.4 ±
14.1 ng/mg Cre, respectively (Figure 4C).
Plasma ARA-metabolites were also unchanged from
the initial levels during the supplementation and showed
no differences at 2 and 4 weeks among the three groups.
The initial concentrations of PGE2 in the placebo, the
l o w - A R Aa n dt h eh i g h - A R Ag r o u p sw e r e8 . 1 2±1 . 9 6 ,
9.52 ± 2.48 and 10.9 ± 3.79 pg/mL, respectively (Figure
4D), and those of LXA4 were 11.9 ± 10.8, 25.4 ± 50.0
and 19.9 ± 18.7 pg/mL, respectively (Figure 4E), respec-
tively. After the supplementation for 4 weeks, the con-
centrations of PGE2 and LXA4 in the low-ARA group
were 8.37 ± 2.40 (Figure 4C) and 20.4 ± 17.1 pg/mL,
respectively (Figure 4E); those in the high-ARA group
were 8.44 ± 2.33 (Figure 4C) and 17.7 ± 10.7 pg/mL,
respectively (Figure 4E).
None of the ARA metabolites measured in urine and
blood measured was correlated with ARA contents in
plasma phospholipids at 4 weeks of ARA supplementa-
tion (Figure 5).
Discussion
The present study clarified that in spite of the increase
in ARA levels in plasma phospholipids, plasma clinical
parameters of cardiovascular, inflammatory and allergic
diseases and levels of ARA metabolites in urine and
(A) PT 
70 
80 
90 
100 
110 
120 
0  2  4  6  8 
Time (week) 
P
T
 
(
%
)
 
(B) APTT 
20 
25 
30 
35 
40 
45 
50 
0  2  4  6  8 
Time (week) 
A
P
T
T
 
(
s
e
c
)
 
(C) ATIII 
80 
90 
100 
110 
120 
130 
140 
0  2  4  6  8 
Time (week) 
A
T
I
I
I
 
(
%
)
 
(D) Hs-CRP 
0 
100 
200 
300 
400 
500 
600 
0  2  4  6  8 
Time (week) 
H
s
-
C
R
P
 
(
P
g
/
d
L
)
 
(E) Adiponectin 
0 
5 
10 
15 
20 
25 
0  2  4  6  8 
Time (week) 
A
d
i
p
o
n
e
c
t
i
n
 
(
P
g
/
m
L
)
 
(F) SBP 
80 
100 
120 
140 
160 
0  2  4  6  8 
Time (week) 
S
B
P
 
(
m
m
H
g
)
 
(G) DBP 
40 
60 
80 
100 
120 
0  2  4  6  8 
Time (week) 
D
B
P
 
(
m
m
H
g
)
 
(H) IgE 
0 
200 
400 
600 
800 
0  2  4  6  8 
Time (week) 
I
g
E
 
(
I
U
/
m
L
)
 
(I) EO 
0 
2 
4 
6 
8 
10 
0  2  4  6  8 
Time (week) 
E
O
 
(
%
)
 
(J) CRP 
0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
0  2  4  6  8 
Time (week) 
C
R
P
 
(
m
g
/
d
L
)
 
(K) IL-6 
0 
5 
10 
15 
20 
25 
0  2  4  6  8 
Time (week) 
I
L
-
6
 
(
p
g
/
m
L
)
 
(L) TNFD
0 
0.5 
1.0 
1.5 
2.0 
0  2  4  6  8 
Time (week) 
T
N
F
D
 
(
p
g
/
m
L
)
 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
Supplementation 
a 
b 
ab 
ab 
a 
b  **  ** 
* 
**  ** 
** 
**  ** 
** 
**  ** 
** 
* 
**  * 
ab 
a 
b 
**  **  ** 
** 
**  ** 
*  * 
Placebo  
Low-ARA  
High-ARA  
Figure 3 Plasma parameters for cardiovascular (A-G), allergic (H-I) and inflammatory (J-L) diseases during 4-week supplementation
and 4-week washout. Placebo, low-ARA and high-ARA groups are indicated by open circles, closed diamonds and closed squares, respectively.
Values are means ± SD (n = 20 (placebo) and n = 22 (in each low- and high-ARA group)). *p < 0.05, **p < 0.01 vs. baseline in group (ANOVA
and Dunnett’s test). Values without a common letter are significantly different at p < 0.05 (ANOVA and Tukey-Kramer test).
Kakutani et al. Lipids in Health and Disease 2011, 10:241
http://www.lipidworld.com/content/10/1/241
Page 7 of 12blood were not altered among the healthy elderly parti-
cipants whose diet was supplemented with an ARA-
enriched oil (240 or 720 mg/day ARA) for 4 weeks.
In previous studies, ARA content in plasma phospholi-
pids increased by 0.7% in young females supplemented
with 80 mg/day of ARA for 3 weeks [31], 2.0% in elderly
males given 240 mg/day of ARA for 4 weeks [6], and by
4.3% in adult males given 838 mg/day of ARA for 4
weeks [23]. In the present study, supplementation with
240 and 720 mg/day of ARA increased ARA content by
2.54% and 5.56%, respectively (Figure 2), which was con-
sistent with these findings. These results suggest that
age or gender of participants has little effect of ARA
supplementation on the incr e a s ei np l a s m aA R Ac o n -
tent. The results also suggest that the plasma ARA con-
tent increases dose-dependently with ARA up to at least
around 800 mg/day. The ARA content in plasma phos-
pholipids increased at 2 weeks and was almost the same
between at 2 weeks and 4 weeks. The elevated ARA
content decreased to almost the initial level during the
4-week washout period regardless of an intake of 240
mg/day or 720 mg/day of ARA. These results were simi-
lar to findings seen during intake of 838 mg/day of ARA
[23]. The intake of ARA caused a rapid increase in
plasma ARA levels but more than 2 weeks of supple-
mentation did not result in any further increases. This is
different from DHA, because the velocity of both
increases and decreases in plasma DHA content seems
slower when fish oil is administered and discontinued
during a washout period [32]. The changes in the other
fatty acids were also characteristic since plasma DHA
and EPA contents remained unchanged throughout the
period. The relatively high intake of DHA+EPA
(approximately 1 g/day) in the present study (Table 3)
might also have contributed to maintaining plasma
DHA and EPA levels. The plasma LA content changed
in parallel with the plasma ARA content (Figure 2). A
previous study also noted this phenomenon [23].
Although ARA and DHA are considered to compete
against each other, ARA intake does not reduce plasma
DHA content, whereas intake of DHA and EPA reduces
both plasma ARA and LA contents [32,33]. The
U
r
i
n
e
 
l
i
p
i
d
 
m
e
d
i
a
t
o
r
 
(
n
g
/
m
g
 
C
r
)
 
P
l
a
s
m
a
 
l
i
p
i
d
 
m
e
d
i
a
t
o
r
 
(
p
g
/
m
L
)
 
(B) 2,3-dinor-6-keto PGF1D D  
0 
20 
40 
60 
80 
100 
120 
0 2 4 6 8 
Time (week) 
(A) 11-dehydro TXB2 
0 
0.2 
0.4 
0.6 
0.8 
1.0 
0 2 4 6 8 
Time (week) 
(C) Tetranor-PGEM 
0 
10 
20 
30 
40 
0 2 4 6 8 
Time (week) 
(D) PGE2 
0 
5 
10 
15 
20 
0  2  4  6  8 
Time (week) 
(E) LXA4 
0 
20 
40 
60 
80 
100 
0  2  4  6  8 
Time (week) 
Placebo  
Low-ARA  
High-ARA  
Supplementation  Supplementation  Supplementation 
Supplementation  Supplementation 





Figure 4 Change in ARA metabolites during 4-week supplementation and 4-week washout. (A) Urinary 11-dehydro TXB2, (B) urinary 2,3-
dinor-6-keto- PGF1a, (C) urinary tetranor-PGEM, (D) plasma PGE2 and (E) plasma LXA4. Placebo, low-ARA and high-ARA groups are indicated by
open circles, closed diamonds and closed squares, respectively. Values are means ± SD (n = 20 (placebo) and n = 22 (in each low- and high-
ARA group)). *p < 0.05, **p < 0.01 vs. baseline in group (ANOVA and Dunnett’s test). Values without a common letter are significantly different at
p < 0.05 (ANOVA and Tukey-Kramer test).
Kakutani et al. Lipids in Health and Disease 2011, 10:241
http://www.lipidworld.com/content/10/1/241
Page 8 of 12specificity of incorporation into plasma phospholipids
from dietary fatty acids seems to be in the order of
DHA, EPA > ARA > LA. The reason for the difference
between ARA and DHA incorporation is unclear, but
the specificity of some enzymes associated with acyla-
tion and/or deacylation of each fatty acid might be
involved.
Platelet aggregation remains unaffected by an ARA
intake of 1.5 g/day or 838 mg/day in randomized con-
trolled studies [21,23]. Thep r e s e n ts t u d yf o u n dt h a t
parameters of the coagulation system (PT, APTT and
ATIII) remained unaltered and within the normal range.
Parameters of chronic inflammation such as plasma hs-
CRP, TNFa and IL-6, which are risk factors for cardio-
vascular disease, remained unchanged, as did plasma
adiponectin, which is thought to reduce the risk for car-
diovascular diseases. These results suggest that ARA
intake does not affect the risk for cardiovascular disease.
The parameters for inflammatory diseases (CRP, TNFa
and IL-6) and allergic diseases (IgE and eosinophil) were
similarly unchanged, suggesting that ARA intake does
not evoke inflammatory or allergic diseases.
Furthermore, general blood biochemical and hematolo-
gical parameters remained within normal ranges (Addi-
tional file 1, Table S1). Thus, ARA intake appears to be
safe under the conditions described here.
In this study, we measured TXA2,P G I 2,P G E 2 and
LXA4.T X A 2 causes platelet aggregation and vasocon-
striction, which are considered to lead to cardiovascular
disease, PGI2 competes against TXA2 and suppresses
cardiovascular disease and PGE2 has various physiologi-
cal roles, one of which is an inflammatory trigger in
addition to possible involvement in cancer growth.
LXA4 has effects opposite to PGE2, and reduces inflam-
mation and cancer growth [34]. Considering their asso-
ciation with diseases, we estimated TXA2 and PGI2
production as urinary 11-dehydro TXB2 and 2,3-dinor-
6-keto PGF1a, respectively. The reported urinary con-
centration of 11-dehydro TXB2 is 1.489 ng/mg Cre in
patients with heart failure, 0.632 ng/mg Cre in those
with ischemic heart disease, 0.44 ng/mg Cre in healthy
controls [15] and around 0.6 ng/mg Cre in patients with
essential hypertension and retinopathy [16]. The mean
concentration of 11-dehydro TXB2 throughout the
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Page 9 of 12present study was < 0.4 ng/mg Cre, which was lower
than the levels in these patients and did not significantly
differ among the groups. Urinary 2,3-dinor-6-keto
PGF1a was similarly unchanged and did not differ signif-
icantly among the groups. These results show that an
increase in the ARA content of plasma phospholipids
from 8% to 14% did not affect TXA2 and PGI2 contents.
This is consistent with the finding that parameters for
cardiovascular disease did not change. However, these
findings seem to differ from those of a previous study in
which both urinary 11-dehydro TXB2 and 2,3-dinor-6-
keto PGF1a were slightly increased by intake of 1.5 g
ARA/day for 50 days [22]. The larger dose and longer
study duration might explain the discrepancies between
that study and ours, but the actual reason for the differ-
ence remains unclear.
Several reports have described that plasma PGE2
increases in inflammatory diseases. For instance, the
plasma PGE2 concentration increases to > 40 pg/mL in
patients with ulcerative colitis [17], and to 54.5 pg/mL
in patients with advanced periodontitis [18] compared
with about 10 pg/mL in controls. The plasma PGE2
concentration in the present study was about 10 pg/mL,
which was below the values associated with inflamma-
tory diseases. This value did not change or significantly
differ throughout the study. Urinary concentrations of
tetranor-PGEM, another marker of PGE2 production,
are higher in patients with cancer. The reported level is
11.6 ng/mg Cre in patients with colorectal cancer and
7.0 ng/mg Cre in matched controls [19]. Another study
indicated a urinary tetranor-PGEM concentration of
15.0 ng/mg Cre in patients with colorectal cancer and
7.17 ng/mg Cre in polyp-free controls [35]. The mean
concentration of tetranor-PGEM in the present study
was 8 ng/mg Cre in the placebo and the low-ARA
group, and 14 ng/mg Cre in the high-ARA group which
seems relatively higher compared with normal levels
reported previously. The high level of tetranor-PGEM in
the high-ARA group was due to the three participants
with levels > 30 ng/mg Cre. The higher levels in these
participants were not changed by ARA supplementation
or during the washout period. Thus, tetranor-PGEM
concentration was not significantly changed by ARA
supplementation, indicating that ARA intake does not
affect a candidate marker of colorectal cancer. Plasma
LXA4 in the high-ARA groups was significantly
increased after the washout period (Figure 4E). It was
considered to be unrelated to ARA supplementation
because the increase was also observed in the placebo
group. Plasma LXA4 level may be more variable com-
pared to the other metabolites, but the details are
unclear. The increase was slight and considered not to
affect the state of the participants.
Next, we analyzed correlations between plasma ARA
content and ARA metabolites concentrations after 4
weeks of ARA administration (Figure 5). Concentrations
of each ARA metabolite were distributed across a wide
range, although all participants were healthy volunteers.
None of the values correlated with plasma ARA content
or ARA dose. Several individual values were high, but
these values seemed normal for these patients, because
the high levels in those participants were not changed at
baseline and at 2 and 8 weeks. These results indicate
that the increase in plasma ARA content from 8% to
14% does not increase the production of TXA2,P G I 2,
PGE2 and LXA4. The production of lipid mediators is
not determined primarily by ARA content and seems to
be controlled by other factors.
Diet was assessed to ensure that dietary intake of ARA
and related fatty acids did not differ among the groups
or as a result of the intervention. Participants consumed
170-200 mg/day of ARA from daily meals (Table 3),
which is within the normal reported range [1-3] and
v a l u e sd i dn o td i f f e ra m o n gt h eg r o u p so rw i t ht i m e .
The intakes of DHA and EPA were 300-500 mg/day and
500-800 mg/day, respectively, and also did not differ
among the groups. Although these values are within the
common range in Japan, they are much more than
those in Western countries ([2], [36]). Energy and
macronutrient intake did not differ among the groups
(Table 3), and did not seem to affect the present data.
The effects of ARA supplementation on healthy
elderly were clarified here, but studies of patients with
specific diseases are needed. In summary, blood para-
meters of cardiovascular, inflammatory and allergic dis-
eases, as well as urinary and plasma ARA metabolites
did not change in Japanese healthy elderly participants
who consumed ARA-enriched oil (240 or 720 mg/day of
ARA) for 4 weeks although plasma ARA levels signifi-
cantly increased.
Additional material
Additional file 1: Supplemental Table S1. Physiological parameters
and blood biochemical and hematological parameters
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